Search clinical trials for: 0.3 mg ranibizumab

Total 14410 results

Novartis

Completed

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (EXCITE)

Age Related Macular Degeneration

Switzerland
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
Novartis

Completed

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement (RESOLVE)

Diabetic Macular Edema

Switzerland
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO) (BRAVO)

Macular Edema | Retinal Vein Occlusion
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) (CRUISE)

Macular Edema | Retinal Vein Occlusion
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Southeast Retina Center, Georgia
Genentech, Inc.

Completed

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

Polypoidal Choroidal Vasculopathy

United States
H. Lundbeck A/S

Completed

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Parkinson Disease

United States
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (CADENCE)

Hypertension, Pulmonary

United States, Belgium, France, Germany, Israel, Italy, Spain, Sweden, United Kingdom, Poland, Canada
New England Retina Associates
Genentech, Inc.

Completed

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Choroidal Melanoma

United States
Kowa Company, Ltd.

Completed

A Clinical Pharmacology Study of K-877 Controlled Release Tablet

Dyslipidemias

Japan
University of Texas Southwestern Medical Center
US Department of Veterans Affairs

Completed

Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer

Rectal Cancer

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

Sedation

China
Arshad Khanani
Genentech, Inc.

Completed

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

Diabetic Macular Edema

United States
Ural State Medical University
Ural Institute of Cardiology; De Haar Research Foundation

Terminated

Ranibizumab and the Risk of Arterial Thromboembolic Events (RATE)

Coronary Artery Disease | Cerebrovascular Disorders | Age-related Macular Degeneration

Netherlands, Russian Federation
Kwang Dong Pharmaceutical co., ltd.

Completed

A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

Overactive Bladder

Korea, Republic of
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

Branch Retinal Vein Occlusion

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion

China
Hoffmann-La Roche

Active, not recruiting

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Diabetic Retinopathy

United States, Puerto Rico
Hoffmann-La Roche

Active, not recruiting

This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)

Diabetic Macular Edema

United States
Jaeb Center for Health Research
National Eye Institute (NEI); Genentech, Inc.; Regeneron Pharmaceuticals

Completed

Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (Protocol T)

Diabetic Macular Edema

United States
GlaxoSmithKline

Completed

First Time in Human Study Using GSK2330672

Diabetes Mellitus, Type 2

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema (CONGO)

Diabetic Macular Edema (DME)

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
Opthea Limited

Recruiting

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Republic of, Latvia, Malaysia, Poland, Spain, Thailand, Ukraine, United Kingdom
Shaperon

Completed

Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients

COVID19 Pneumonia

Romania
Quark Pharmaceuticals
Pfizer

Completed

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). (MONET)

Age Related Macular Degeneration

Spain, Korea, Republic of, Turkey, Taiwan, United States, Israel, Austria, Philippines, Denmark, Hong Kong, India
Genentech, Inc.

Completed

An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

Choroidal Neovascularization, Age-related Macular Degeneration
Novartis Pharmaceuticals

Completed

Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients (EXTEND II)

Age Related Macular Degeneration

China
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Novartis Pharmaceuticals

Completed

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL)

Age-Related Macular Degeneration

Australia
Novartis Pharmaceuticals

Completed

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (TIDE AMD)

Wet Age-Related Macular Degeneration

Germany
Charles C Wykoff, PhD, MD
Genentech, Inc.

Completed

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab (T-REX)

Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema (DIVERSE)

Diabetic Retinopathy

Germany
Genentech, Inc.

Completed

An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)

Macular Edema | Retinal Vein Occlusion
Atox Bio Ltd

Terminated

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Acute Kidney Injury | Peritonitis | Necrotizing Soft Tissue Infection

United States, France
Kowa Company, Ltd.

Completed

A Phase III Confirmatory Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
Auris Medical AG

Completed

AM-111 in the Treatment of Acute Inner Ear Hearing Loss (HEALOS)

Hearing Loss

Bulgaria
Novartis Pharmaceuticals

Completed

Canadian Treat and Extend Analysis Trial With Ranibizumab (CAN-TREAT)

wetAMD

Canada
Shaperon

Recruiting

Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients

COVID-19 Pneumonia

Korea, Republic of
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (Blossom)

Macular Edema Secondary to Branch Retinal Vein Occlusion

China, Taiwan, Hong Kong, Philippines, Vietnam, Indonesia
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRYSTAL)

Central Retinal Vein Occlusion | Macular Edema

Greece, Hungary, Turkey, Australia, Austria, Netherlands, United Kingdom, Italy, Spain, Ireland, Portugal, Slovakia, Canada, Switzerland, Czech Republic, Poland, Denmark, Sweden
Novartis Pharmaceuticals

Completed

Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) (SALUTE)

Age-related Macular Degeneration

Turkey
Manhattan Eye, Ear & Throat Hospital
Genentech, Inc.

Completed

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (FVF4140S)

Polypoidal Choroidal Vasculopathy | Pseudoxanthoma Elasticum | Pathological Myopia | Retinal Angiomatous Proliferation | Coats' Disease | Idiopathic Retinal Telangiectasia | Multi-focal Choroiditis | Rubeosis Iridis | Von Hippel Lindau Disease | BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)

United States
Lpath, Inc.

Completed

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (Nexus)

Exudative Age-related Macular Degeneration

United States
Sunstar Americas

Completed

GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

Periodontal Diseases | Alveolar Bone Loss

United States
Autoimmune Technologies, LLC

Completed

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

Influenza

United States
David M. Brown, M.D.
Genentech, Inc.

Completed

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) (DAVE)

Diabetic Macular Edema

United States
University of Rostock

Completed

Influence of the Neuromuscular Blockade on Mask Ventilation

Observation of Neuromuscular Block | Complication of Ventilation Therapy

Germany

3

Subscribe